Do adrenergic alpha‐antagonists increase the risk of poor cardiovascular outcomes? A systematic review and meta‐analysis
Abstract Due to concerns regarding neurohormonal activation and fluid retention, adrenergic alpha‐1 receptor antagonists (A1Bs) are generally avoided in the setting of heart disease, namely, symptomatic heart failure (HF) with reduced ejection fraction (HFrEF). However, this contraindication is main...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-10-01
|
| Series: | ESC Heart Failure |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ehf2.14012 |